942 related articles for article (PubMed ID: 32019317)
1. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
2. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
Henson B; Hollingsworth H; Nevois E; Herndon C
J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
[TBL] [Abstract][Full Text] [Related]
5. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
6. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
[TBL] [Abstract][Full Text] [Related]
7. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
9. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
11. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
12. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
14. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
17. Erenumab in the treatment of migraine.
Jain S; Yuan H; Spare N; Silberstein SD
Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
[TBL] [Abstract][Full Text] [Related]
18. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
Garland SG; Smith SM; Gums JG
Ann Pharmacother; 2019 Sep; 53(9):933-939. PubMed ID: 30813769
[No Abstract] [Full Text] [Related]
19. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
20. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
